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The human population is constantly exposed to multiple influenza A subtypes due to zoonotic spillover and rapid viral evolution
driven by intrinsic error-prone replication and immunological pressure. In this context, antibody responses directed against the
HA protein are of importance since they have been shown to correlate with protective immunity. Serological techniques, detecting
these responses, play a critical role for influenza surveillance, vaccine development, and assessment. As the recent humanpandemics
and avian influenza outbreaks have demonstrated, there is an urgent need to be better prepared to assess the contribution of the
antibody response to protection against newly emerged viruses and to evaluate the extent of preexisting heterosubtypic immunity
in populations. In this study, 68 serum samples collected from the Italian population between 1992 and 2007 were found to be
positive for antibodies against H5N1 as determined by single radial hemolysis (SRH), but most were negative when evaluated using
haemagglutination inhibition (HI) and microneutralisation (MN) assays. As a result of these discordant serological findings, the
increased sensitivity of lentiviral pseudotypes was exploited in pseudotype-based neutralisation (pp-NT) assays and the results
obtained provide further insight into the complex nature of humoral immunity against influenza A viruses.
1. Introduction
The constant rapid evolution of HPAI H5 and H7 viruses
driven by intrinsic error-prone replication and increased by
immune pressure significantly influences the sensitivity of
available serological assays. Moreover, the antigenic variation
of influenza viruses can also limit the efficacy of prepandemic
human vaccines, vaccine strain selection, and results in the
necessity to update influenza vaccines to include contempo-
rary viruses and to monitor those that are distinct from the
current vaccine strains [1]. The human population is con-
stantly exposed, during a lifetime (by natural infection and/or
vaccination) to different influenza A subtypes with an associ-
ated increase in the memory B cell repertoire. This antibody
repertoiremay also be cross-reactive to closely related variant
viruses making it more difficult to develop sensitive and
specific serological assays [2–4]. The adaptive homosubtypic
antibody responses to the antigenic sites of the HA andNA of
individual influenza strains can discriminate between influ-
enza subtypes and current seasonal influenza vaccines can
boost strain-specific responses with little protection against
antigenically drifted or shifted strains. However, it has been
shown that exposure to one subtype of influenza A can
also induce immunity that is cross-protective against other
influenza subtypes. Such adaptive immune response, called
“heterosubtypic” immunity, elicits an antibody response to
epitopes that are highly conserved amongst strains [5–7].
Thesemore conserved epitopes, which are less accessible than
those on the HA globular head, are predominantly localized
in the membrane-proximal stalk region of HA [8]. From
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2009 until recently, many anti-stalk antibodies have been
structurally analyzed [9–12] and increased attention has been
focused to understand if this heterosubtypic immunity can
confer a level of human population immunity, preventing
certain avian subtypes from becoming pandemic with less
potential for promoting immune escape mutants [13] and on
the role of such antibodies in the development of cross-
protective human vaccines [14]. As the recent pandemics and
avian influenza outbreaks demonstrated, there is a need to be
better prepared to assess heterosubtypic and homosubtypic
antibody responses to newly emerged viruses and to evaluate
the extent of preexisting serological cross-reactivity in popu-
lations [15] as well as the lack of life-long immunity against
influenza A viruses [10]. Additionally, from a public health
point of view, it is important to determine if the immunolog-
ical profiles of these responses can be detected using a com-
bination of serological assays that can be subsequently used
to promote vaccine efficacy testing and licensure. Influenza
serological assays not only are routinely employed for
virus characterization, vaccine strain selection, and vaccine
evaluation but can also be exploited for assessing the compos-
ite nature of antibody responses generated against influenzaA
viruses, specific risk factors for infection, and rates of trans-
mission in defined populations [2]. During the last decade,
it has been approved by WHO and collaborating centers for
influenza that studies on influenza vaccine efficacy should
include endpoints that reflect a broad range of immune
responses as a surrogate of protection, since protection
represents the sum of various immune responses (including
antibody and cell-mediated responses) and that there is
the need to overcome limitations of the current available
serological assays. To date, serum antibodies against the HA
globular head are the onlywell-characterized andwidely used
correlates of protection while other correlates still need to be
established for antibody responses against the HA stem
regions, NA and M2 [16, 17]. The HI test is the most widely
used assay due to its relative simplicity and although there is
not an absolute titre that guarantees protection, the serum
antibody titre of≥1 : 40 remains associatedwith protection for
inactivated influenza vaccines [18]. In the European commu-
nity (EU) the SRH assay is also employed as an alternate sero-
logical assay for the evaluation of influenza vaccines [19, 20].
Undoubtedly, the need to develop effective pandemic vac-
cines and their evaluation in preclinical and clinical studies
has raised questions. These primarily concern the evaluation
of influenza vaccine immunogenicity and effectiveness in
populations that are negative at baseline and in specific age
groups (i.e., children and elderly people) [21, 22] or in
sero-positive populations (before vaccination) where the
same parameters may under- or overestimate the antibody
responses [23]. Additionally, heterosubtypic responses can
make interpretation of serological data more problematic. In
light of this, international collaborative studies have been
carried out not only to evaluate the reproducibility of current
serological assays aiming to improve specificity, sensitivity,
and interassay variability [20, 24] but also to reconsider
certain criteria used for the evaluation of pandemic influenza
vaccines which rely in essence on immunological endpoints
that were derived for seasonal influenza vaccines [25].
In order to understand the contribution of broadly
neutralizing “heterosubtypic” antibodies [26] and due to the
initially observed lower sensitivity demonstrated for measur-
ing anti-H5 antibody responses [27, 28] together with the
requirements for working with highly pathogenic avian
strains (Biosafety Level 3 (BSL3) laboratories), comparative
serological studies have been carried out. These involve
standard serological assays (SRH,HI, andMNassays) and the
more recent pp-NT assay [28–31]. Influenza pseudotypes
bearing HA and NA envelope glycoproteins devolved from
the rest of the virus have been demonstrated to be ideal tools
to monitor the effects of viral evolution on serological out-
comes and can be used in parallel with other serological tests
(HI, MN, and SRH), for accurate sequence-directed, sen-
sitive, and low-containment assays for measuring antibody
responses against influenza H5 and H7 HA and/or NA. It is
relatively straightforward to update the pseudotype-based
HA neutralization assay to measure responses against newly
emergingH5 andH7 viruses [30, 32]. Pp-NT assays have been
previously shown to have broad utility for the detection of
neutralizing antibody responses in avian and human sera
against both avian and human influenza viruses [31, 33, 34].
More specifically, pp-NT assays have been shown to be effi-
cient for the measurement of broadly neutralizing antibodies
directed against the HA stalk of influenza making them ideal
serological tools for the study of cross-reactive responses
against multiple influenza subtypes with pandemic potential
[11, 35]. As described in the following study, influenza
pseudotypes have been used to detect neutralizing antibody
responses against HPAI H5 and H7 strains in human sera.
These sera were found positive by SRH assay but the majority
were negative when tested by well-established HI and MN
assays, although this cohort of individuals has neither been
vaccinated with a prepandemic H5N1 vaccine nor likely to
have ever been exposed to H5N1 viruses [36].
2. Materials and Methods
2.1. Serum Samples. A panel of human sera was provided by
Professor Emanuele Montomoli (Department of Molecular
and Developmental Medicine, University of Siena, Italy), and
this collection conformed to Italian ethics law. It consisted
of 68 sera collected from Italian subjects (age between 6
months and 92 years old) from 1992 to 2007 that were
previously found to be positive against HPAI H5N1
A/Vietnam/1194/2004 as determined by the SRH assay. The
sero-positivity of these sera was also confirmed by removing
nonspecific antibodies by their adsorption with a 1 : 1
volume mixture of A/New Caledonia/20/1999 H1N1 and
A/California/7/2004 H3N2 viruses [36]. The positive
controls used in pp-NT assays were reference sheep sera
against A/England/427/1988 (H3N2) and NIBRG-14 (H5N1)
provided by the National Institute for Biological Standards
and Control (NIBSC, United Kingdom), avian sera against
A/African starling/England/983/1979 (H7N1) provided by
the Animal Health and Veterinary Laboratories Agency
(AHVLA), and monoclonal antihuman influenza A (H1N1,
H2N2) antibody (mAb C179) (Takara, Clonotech). The
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negative control used in the pp-NT assay was Foetal Bovine
Serum.
2.2. Pseudotype Construction and Firefly Luciferase pp-
NT Assays. Lentiviral pseudotypes with HA glycoproteins
derived from HPAI virus A/Vietnam/1194/2004 (H5N1),
A/Indonesia/5/2005 (H5N1), and HPAI virus A/chicken/
Italy/13474/1999 (H7N1) were produced by cotransfection
of 293T/17 cells with the respective HA plasmid (pI.18
backbone), the HIV gag-pol plasmid p8.91, and the reporter
plasmid pCSFLW (expressing Firefly luciferase) using the
Fugene-6 transfection reagent. Neuraminidase activity was
provided by exogenous bacterial NA addition for the release
of pseudotypes from producer cells. Serum samples (2.5 𝜇L)
were twofold serially diluted in culture medium and mixed
with pseudotype virus (1 × 106 (RLU) luciferase input) at a
1 : 1 v/v ratio. After incubation at 37∘C for 1 hr, 1 × 104
293T/17 cells were added to each well of a white 96-well flat-
bottomed tissue culture plate. RLU were evaluated 48 hr later
by luminometry using the Bright-Glo assay system (Promega,
UK). End-point neutralizing antibody titres were calculated
using GraphPad Prism 6. IC
50
pseudotype neutralization
titres are expressed as the reciprocal of the serumdilution that
results in a 50% inhibition of pseudotype virus entry.
2.3. Single Radial Haemolysis (SRH) Assays. For the SRH
assays, agarose immunoplates were prepared with sheep and
turkey erythrocytes 10% (v/v of assay buffer) sensitized by
inactivatedwhole virus (antigens used:A/Vietnam/1194/2004
andA/Indonesia/5/2005) andwith the addition of 5% guinea-
pig complement. The amount of antigen was diluted in PBS
to reach a final concentration of 2000HU/mL.The size of the
haemolysis zone around the well containing the serum is
measured in mm and the diameter of haemolysis is then
transformed in area (mm2) by using a Transidyne Calibrating
Viewer (Transidyne General Corporation, Ann Arbor, MI).
2.4. Inhibition ofHaemagglutination (HI) Assays. Thehaema-
gglutination inhibition (HI) assay was performed according
to WHO recommendation [37] and described previously
[38] using whole inactivated virus for the H5N1 strains:
A/Vietnam/1194/2004 and A/Indonesia/5/2005.
2.5. Microneutralization (MN) Assays. Microneutralization
(MN) assays were performed as previously described [27, 39]
using wild type H5N1 A/Indonesia/5/2005 (homologous
strain of subclade 2.1 provided byCDC,Atlanta,GA) andwild
type H5N1 A/Vietnam/1194/2004 (homologous strain of sub-
clade 1 provided by the CDC).
3. Data and Statistical Analysis
The end-point neutralizing antibody titres obtained by pp-
NT assays were calculated and IC
50
pseudotype neutraliza-
tion titres were expressed as the reciprocal of the serum
dilution that resulted in a 50% inhibition of pseudotype virus
entry. For the panel of 68 sera (collected from Italian subjects
between 1992 and 2007), the IC
50
values obtained by
pp-NT assay for different influenza strains were reported
on Box-and-Whisker plots. When one-way ANOVA test
was required, a nonparametric multicomparison one-way
ANOVAwas performed. Also, IC
50
values obtained from pp-
NT assays were reported on dot plot graphs and Pearson’s cor-
relation analysis was used to assess the correlation between
pp-NT and HI titres, between pp-NT titres and SRH areas or
between pp-NT titres and MN titres. All the analyses were
performed by using Prism version 6 (GraphPad Software,
Version 6, San Diego, CA). SRH results were considered
negative in the absence of haemolysis or with an haemol-
ysis area <4mm2 (2.256mm diameter), positive, but not
sero-protective, with an haemolysis area between 4mm2 and
25mm2 (diameter between 2.25mm and 5.65mm), positive
and sero-protectivewith haemolysis area≥25mm2 (diameter≥
5.65mm). HI titres were defined as the reciprocal of the
highest dilution resulting in complete inhibition of haemag-
glutination. HI titres were evaluated according to the EU
EMEA CHMP criteria [40]. For MN assay, sera were tested
at an initial dilution of 1 : 20 and those that yielded negative
results were assigned a titre of 10.
4. Results
4.1. HPAI H5 and H7 Influenza Pseudotype Production. For
this study, lentiviral pseudotype particles were constructed as
described previously [30, 32, 41] with the neuraminidase
activity provided by exogenous bacterial NA addition. Pseu-
dotype viruses were produced by cotransfection of human
embryonic kidney (HEK) 293T/17 cells with the respec-
tive HA plasmids (HPAI H5N1 A/Vietnam/1194/2004 (clade
1), A/Indonesia/5/2005 (clade 2.1.3.2), and HPAI H7N1
A/chicken/Italy/13474/1999), the HIV gag-pol plasmid p8.91,
and the lentiviral vector pCSFLW (expressing Firefly luci-
ferase). A subset from the panel of 68 serum samples
(with pp-NT titre range ≥320–640 when tested using H5N1
A/Vietnam/1194/2004) was additionally tested using influ-
enza pseudotypes bearing the HAs from H3N2 A/Udorn/
307/1972 and H1N1 A/South Carolina/1/1918.
4.2. Measurement of Neutralizing Antibodies by pp-NT Assays
and Comparison between Serological Assays (Study Sera
Collected from Italian Subjects between 1992 and 2007).
For each pseudotype tested (H5N1 A/Vietnam/1194/2004,
A/Indonesia/5/2005, and H7N1 A/chicken/Italy/13474/1999),
individual IC
50
values were reported as titre ranges (from<40
to 5120–10240) (Figure 3). The H5 pseudotypes were com-
pletely neutralized by the H5 sheep sera (NIBRG-14 H5N1)
at a 1 : 1280 dilution but not by the H7 antisera (A/African
starling/England/983/1979) whilst the H7 pseudotype was
completely neutralized by the H7 antisera at a 1 : 1280 dilu-
tion but not by the H5 sheep sera. In the absence of an
appropriate sera control for H5 A/Indonesia/5/2005 and
A/SouthCarolina/1/1918, C179mABwas used, andH1 andH5
pseudotypes were neutralized with IC
50
values ranging
between 640–1280 and 1280–2560. Negative controls (Foetal
Bovine Serum) did not show any neutralization.
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The neutralizing antibody titres against the Group 1
H5N1 clade 1 A/Vietnam/1194/2004 pseudotype ranged from
<40 (cutoff) to 1 : 5120–10240 and 7/68 (10.3%) sera were
found to be negative while antibody titres against Group 1
H5N1 clade 2.1.3.2 A/Indonesia/5/2005 ranged from <40 to
640–1280 and 36/68 (53%) sera were found to be negative.
IC
50
neutralizing antibody titres against the Group 2 H7N1
A/chicken/Italy/13474/1999 pseudotype ranged from <40 to
1 : 160–320. 47/68 (69.1%) sera were found to be negative
against A/chicken/Italy/13474/99 (Figure 3). Each individual
serum sample tested against both H5 pseudotypes (subclades
1 and 2.1.3.2) and H7 pseudotype was also assigned a colour
depending on the magnitude range (legend, Figure 3) in
order to visualize the antibody titre range obtained for each
serum sample against different influenza pseudotypes. The
darker colours related to higher IC
50
titres while lighter
colours represented negative or lower neutralizing antibody
responses and this allowed an immediate visualisation of the
different antibody responses against HAs from HPAI H5
influenza pseudotypes compared to those obtained against
HPAI H7 pseudotypes.
To explore the potential ability of influenza pseudotypes
to detect heterosubtypic immune responses, neutralising
antibody responses were evaluated not only against HPAI
influenza pseudotypes but also against pseudotypes bearing
HAs belonging to H1 and H3 subtypes. The individual
IC
50
titres of 37 sera (with pp-NT titres against A/Vietnam/
1194/2004 H5 ≥320–640) were tested against Group 1 H1N1
A/South Carolina/1/1918 and Group 2 H3N2 A/Udorn/
307/1972 and ranged from ≥40–80 to ≥2560–5120 and from
≥320–640 to ≥10240, respectively (Figure 4). All 37 sera
resulted positive when tested by pp-NT assay. The IC
50
values obtained for H1, H5 (from clades 1 and clade 2.3.1.2),
H3, and H7 (expressed as medians and reported on Box-
and-Whisker plots in Figure 1) were also analysed using
nonparametric one-way ANOVA revealing no statistical dif-
ferences between Group 1 influenza pseudotypes H1 A/South
Carolina/1/1918 and H5 A/Vietnam/1194/2004 (𝑃 = 0.05),
and H5 A/Indonesia/5/2005 (𝑃 = 0.05) and between H5
A/Indonesia/5/2005 andH7 (𝑃 = 0.05), while statistically sig-
nificant differences were found betweenH1–H3 (𝑃 < 0.0001),
H1–H7 (𝑃 < 0.0001), H5–H7, and H5–H3 pseudotypes (𝑃 <
0.0001).
With reference to SRH assay data, titres measured against
the A/Vietnam/1194/2004 and A/Indonesia/5/2005 viruses
ranged from 28.3mm2 to 78.5mm2 and from 3.9mm2 to
78.5mm2, respectively. All the subjects were classed as sero-
protected against HA A/Vietnam/1194/2004 while 36 sera
were scored with a value corresponding to ≤4mm2; 11
subjects were positive but not sero-protected and 26 positive
and sero-protected when tested against A/Indonesia/5/2005
(Table 1). By HI assay, excluding a single serum sample with
a titre of 1 : 80 and two samples with a titre of 1 : 40, all other
sera were found to be negative (HI titres≤ 1 : 8, titre = 5) when
tested against the A/Vietnam/1194/2004 virus. The HI results
obtained for clade 2.1.3.2 H5 A/Indonesia/5/2005 mirrored
those obtained by clade 1 H5 A/Vietnam/1194/2004 (Table 1).
Similar results were found when the same panel of 68 sera












































































values (reported for each single virus as
medians) obtained when 37 sera (with IC
50
titres against H5
A/Vietnam/1194/04 H5 ≥ 320–640) were tested against H1, H5
(clade 1 and clade 2.1.3.2), H3, and H7 influenza pseudotypes and
analysed by GraphPad using a nonparametric multicomparison
one-way ANOVA test.
(MN titres = 7.01) against H5 A/Indonesia/5/2005 while a
broad spectrum of antibody titres was detected against H5
A/Vietnam/1194/2004 although the majority of subjects were
found negative or non sero-protected (MN titre ≤ 1 : 80),
according to the proposed immune correlates of protection
against H5N1 viruses for MN assays [25]. In detail, 7 subjects
were found sero-protected (MN titres from ≥113 to 452.5), 16
were negative (MN titres ≤ 10), and 45 subjects hadMN titres
ranging between 14.1 and 56.5 (Table 1).
With all IC
50
values (expressed as antibody titre range)
the percentage of subjects (sero-responder) achieving a pp-
NT titre ≥1 : 40, ≥1 : 80, ≥1 : 357 (which corresponds for pp-
NT assay to the proposed threshold of protective antibodies
(1 : 80) for MN assay) [30], and ≥20 were calculated and
depending on these cutoff values, neutralizing antibody
responses against different HAs were evaluated (Table 2). For
a cutoff of 1 : 40, positive sera were found against H5 A/
Vietnam/1194/2004 (61/68), A/Indonesia/5/2005 (42/68), and
H7 A/chicken/Italy/13474/1999 (22/68). 37 sera, positive
against H5A/Vietnam/1194/2004 (titre ≥ 320–640), were also
found positive against H3 (37/37) and H1 pseudotypes
(37/37).
For a cutoff of 1 : 80: 56/68 sera were positive against H5
A/Vietnam/1194/2004, 30/68 against A/Indonesia/5/2005,
12/68 against H7 A/chicken/Italy/13474/1999, 37/37 against
H3, and 34/37 positive against H1. When a cutoff 1 : 357 is
chosen: positive sera were again detected against H5
A/Vietnam/1194/2004 (36/68) and 14/68 against A/Indon-
esia/5/2005 and all sera were found negative against H7
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Table 1: Panel of human sera tested by three different serological assays: SRH, HI and MN. For each assay, H5N1 strains belonging to clade 1
(A/Vietnam/1194/04) and clade 2.1.3.2 (A/Indonesia/5/05) were used. Anti-H5N1 responses were expressed as antibody titres for HI andMN





















SI-101 28.274 28.274 5 5 7.071 7.071
SI-102 28.274 25.967 Serum not enough Serum not enough Serum not enough 7.071
SI-103 50.265 14.186 5 5 7.071 7.071
SI-104 28.274 28.274 5 5 452.548 7.071
SI-105 63.617 78.540 5 5 5.000 7.071
SI-106 63.617 50.265 5 5 56.569 7.071
SI-111 78.540 56.745 5 5 5.000 7.071
SI-112 50.265 44.179 5 5 28.284 7.071
SI-113 38.485 3.997 5 5 28.284 7.071
SI-115 50.265 12.566 5 5 5.000 7.071
SI-117 50.265 50.265 5 5 28.284 7.071
SI-120 63.617 12.566 5 5 452.548 7.071
SI-121 78.540 12.566 5 5 5.000 7.071
SI-122 50.265 25.967 5 5 56.569 7.071
SI-123 38.485 33.183 5 5 28.284 7.071
SI-124 28.274 12.566 5 5 14.142 7.071
SI-125 28.274 23.758 5 5 28.284 7.071
SI-126 38.485 9.621 5 5 7.071 7.071
SI-127 50.265 63.617 5 5 7.071 7.071
SI-128 38.485 44.179 5 5 56.569 7.071
SI-129 38.485 56.745 5 5 28.284 7.071
SI-131 63.617 3.997 5 5 28.284 7.071
SI-132 50.265 50.265 5 5 7.071 7.071
SI-133 28.274 33.183 5 5 28.284 7.071
SI-134 38.485 33.183 5 5 14.142 7.071
SI-137 28.274 3.997 Serum not enough Serum not enough Serum not enough 7.071
SI-138 28.274 38.485 Serum not enough Serum not enough Serum not enough 7.071
SI-139 38.485 56.745 Serum not enough Serum not enough 56.569 7.071
SI-140 28.274 3.997 5 5 28.284 7.071
SI-141 50.265 3.997 5 5 7.071 7.071
SI-142 28.274 3.997 5 5 Serum not enough 7.071
SI-143 50.265 3.997 5 5 28.284 7.071
SI-144 63.617 3.997 5 5 56.569 7.071
SI-145 50.265 7.069 5 5 28.284 7.071
SI-146 28.274 44.179 5 5 56.569 7.071
SI-147 28.274 3.997 5 5 28.284 7.071
SI-148 28.274 3.997 5 5 56.569 7.071
SI-149 38.485 3.997 5 5 113.137 7.071
SI-150 50.265 3.997 5 5 56.569 7.071
SI-151 28.274 12.566 5 5 14.142 7.071
SI-152 38.485 3.997 5 5 14.142 7.071
SI-153 28.274 7.069 5 5 14.142 7.071
SI-155 38.485 12.566 40 5 7.071 7.071
SI-156 28.274 3.997 5 5 28.284 7.071






















SI-157 28.274 3.997 5 5 14.142 7.071
SI-158 50.265 7.069 40 5 7.071 7.071
SI-159 28.274 12.566 5 5 56.569 7.071
SI-160 28.274 3.997 5 5 56.569 7.071
SI-161 50.265 3.997 5 5 28.284 7.071
SI-162 28.274 3.997 5 5 7.071 7.071
SI-163 28.274 3.997 5 5 28.284 7.071
SI-164 38.485 3.997 5 5 113.137 7.071
SI-165 28.274 63.617 5 5 113.137 7.071
SI-166 28.274 3.997 5 5 56.569 7.071
SI-167 28.274 3.997 5 5 56.569 7.071
SI-168 63.617 3.997 5 5 56.569 7.071
SI-169 50.265 3.997 5 5 56.569 7.071
SI-170 38.485 3.997 5 5 56.569 7.071
SI-171 28.274 3.997 5 5 7.071 7.071
SI-172 28.274 3.997 5 5 28.284 7.071
SI-173 38.485 3.997 5 5 28.284 7.071
SI-174 50.265 3.997 80 5 113.137 7.071
SI-175 50.265 3.997 5 5 28.284 7.071
SI-176 28.274 3.997 5 5 113.137 7.071
SI-177 38.485 3.997 5 5 56.569 7.071
SI-178 28.274 3.997 5 5 56.569 7.071
Table 2: Panel of 68 sera collected from Italian population between 1992 and 2007 and tested against H1, H5, H3, and H7 influenza

























































∗HI positive cut-off which defines sero-protection in adults for seasonal vaccines [25].
∗∗Proposed positive threshold for MN assay used to test human sera against HPAI strains [41].
∗∗∗Corresponds for pp-NT assay to the proposed threshold of 1 : 80 for MN assay as previously shown [30].
∗∗∗∗Positive cut-off suggested for the study of hetero-subtypic antibody responses by using influenza pseudotyped particles [14].
pseudotypes. Sera tested against H3 were all positive while
25/37 sera were positive against H1 pseudotypes when the
same cutoff was used (1 : 357). Additionally, a further cutoff
(≥20)was included based on a previous studywhere influenza
pseudotypes have been employed for detecting heterosub-
typic responses [14] and resulted in a higher number of
positive sera against all strains: 67/68 for H5 A/Vietnam/
1194/2004, 44/68 for A/Indonesia/5/2005, 53/68 for H7
A/chicken/Italy/13474/1999, and 37/37 for both H1 and H3
strains (Table 2).
In order to assess whether the results obtained with the
pp-NT assay reflected those obtainedwith conventional sero-
logical assays (using H5 A/Vietnam/1194/2004), data were
compared to those obtained by HI, SRH, and MN assays
(using the corresponding H5 A/Vietnam/1194/2004 strain).
Pearson’s correlation test was performed to measure the
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SRH area >25mm2 = sero-protection








































HI titre of 1 : 40 = 50% protection for
seasonal vaccines
































Figure 2: (a) Comparison of SRH assay versus pp-NT assay for antibody responses against the A/Vietnam/1194/04 antigen. SRH titres
expressed as diameter of haemolysis (in mm2) are plotted on the 𝑋-axis. SRH titres > 25mm2 are considered to be sero-protective and
this cutoff is represented on the plot by a vertical dotted line. IC
50
pseudotype neutralization titres expressed as the reciprocal of the serum
dilution that results in a 50% inhibition of pseudotype virus entry are plotted on the 𝑌-axis; (b) comparison of HI assay versus pp-NT assay
for antibody responses against the A/Vietnam/1194/04 antigen. HI titres expressed as the reciprocal of the highest dilution causing complete
inhibition of haemagglutination are plotted on the 𝑋-axis. IC
50
pseudotype neutralization titres expressed as the reciprocal of the serum
dilution that results in a 50% inhibition of pseudotype virus entry are plotted on the 𝑌-axis; (c) comparison of MN assay versus pseudotype-
based neutralization assay for antibody responses against the A/Vietnam/1194/04 antigen. The vertical dashed lines indicate the value of MN
log 10 titre = 1.9 (corresponding to a titre of 1 : 80) and the proposed threshold of protective antibodies; horizontal dashed line indicates the
corresponding value of pp-NT log 10 titre = 2.55 (corresponding to a titre of 1 : 357).
significance of the correlationswith all data obtained from the
panel of 68 sera. When results from pp-NT assay were com-
pared to those obtained from SRH assay, no correlation was
observed although both assays detected positive responses
(SRH areas > 25mm2 and pp-NT proposed cutoff > 40)
(Figure 2); therefore, both assays were able to detect antibody
responses against the analogous HPAI H5 strain.
Different serological results were obtained with pp-NT
and HI assay where no correlation between assays was found
but, unlike the situation with SRH, predominantly negative
responses were detected as shown in Figure 2. Finally the
result of the analysis (which compares pp-NT titres and MN
titres) revealed no statistically significant correlation between
antibody titres obtained with pp-NT and those obtained by
MN (Figure 2). As described previously, the majority of sera
were negative by MN compared to the positive responses
detected by pp-NT assay.
5. Discussions and Conclusions
In this study, preexisting serological cross-reactivity against
HPAI influenza viruses in human populations has been
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evaluated using a comparative serology approach. Initially,
lentiviral pseudotypes have been used to investigate the neu-
tralizing antibody responses against HPAI influenza viruses
belonging to subtypeH5 (clade 1H5N1A/Vietnam/1194/2004
and clade 2.1.3.2 H5N1 A/Indonesia/5/2005) and subtype H7
(H7N1 A/chicken/Italy/134734/1999) and were employed for
the screening of human sera collected from 1992 to 2007 in
the Italian population [36].
The use of H5 and H7 influenza pseudotypes allowed the
measurement of neutralizing antibody responses against two
antigenically distinct HPAI HAs (belonging to HA Group 1
and 2). The individual components employed for the con-
struction of the pseudotypes used for this assay have been
chosen from a set of interchangeable plasmidsmany of which
we have used for serological assay development previously
[32, 33]. Because this study aimed to look at the composite
nature of neutralizing antibodies responses against differ-
ent influenza HAs and possibly detect antibody responses
against the HA globular head and HA stem region, the NA
activity was provided by exogenous bacterial NA. Therefore,
influenza pseudotypes expressing HA only employed in this
study did not take into consideration the contribution of
anti-NA antibody responses. Due to a logistical difficulty of
obtaining a panel of true negative sera (from 1-year-old chil-
dren, gathered by laboratory analyses in 1965) previously used
for the SRH assay [36], hyper-immune sheep and avian sera
raised against H5 and H7 viruses were employed as con-
trols and they effectively neutralized cognate clade pseudo-
types. This demonstrated a lack of antigenic cross-reactivity
between these two subtypes being consistent with the HAs of
H5 andH7 viruses belonging to two separate groups (Groups
1 and 2) and based on phylogenetic relationship analysis of
currently described HA subtypes [42]. It was known that
antibodies present in these hyper-immune sera were pre-
dominantly haemagglutination inhibition (HI) competent
antibodies [43] that target the globular head of HA, thus
inhibiting pseudotype entry into 293T/17 cells.
A comparative serology approach was undertaken by us
for a prior study [30] where it was shown that in the context
of a prepandemic vaccine trial, the pp-NT assay and the SRH
assay exhibit significant correlation (𝑟 = 0.70, 𝑛 = 226),
which was also seen with HI (𝑟 = 0.73) and MN (𝑟 = 0.78).
In order to determine if a similar degree of correlation can be
obtained when these serological assays (SRH, pp-NT, HI, and
MN assays) are employed for the study of antibody responses
against A/Vietnam/1194/2004 in human subjects that have
neither been vaccinated with a prepandemic H5N1 vaccine
and that are unlikely to have ever been exposed to H5N1
viruses due to geographical locality (Italy), serum samples
from Italian subjects that had previously been found positive
by SRH against A/Vietnam/1194/2004 (titres > 25mm2) were
screened via pp-NT assay. Interestingly, the H5 antibody
responses measured by the two assays in this context did not
correlate as can be seen in Figure 2 where the plot showed
that at each SRH point (28.3, 38.5, 50.3, 63.6, and 78.5mm2)
a wide range of pseudotype IC
50
neutralization titres can be
observed. As expected, similar results were observed when
IC
50
neutralization titres obtained when the same panel
of sera was tested against HPAI H5 influenza pseudotypes
belonging to different clade 2.1.2.3 (A/Indonesia/5/2005).
Although a certain agreement was evidenced between SRH
and pp-NT assays, the magnitude of antibody response
was lower compared to that seen against H5A/Vietnam/1194/
2004 (as shown in Figures 3 and 4). Making direct compar-
isons between the two assays more complicated, SRH has
been shown to detect not only antibody responses against the
HA but also nonspecific antibody responses that are likely to
have been elicited against NA and internal proteins such as
NP and M [44, 45] whilst the pseudotypes used in this study
do not have NA on their surface (unlike in the SRH) so any
antibody responses detected using this assay are directed
solely against the HA. However, results obtained when this
panel of sera was tested using SRH and pp-NT assays sug-
gested that a different mechanism of neutralization could be
supported. In fact, when influenza pseudotypes were used,
they have potentially detected antibody responses directed
against epitopes not exposed on the HA globular head.
Evidence for this was inferred by the marked absence of
correlation when results obtained by pp-NT for both HPAI
H5 strains were compared to those obtained by HI assay
(Figure 2). The lack of correlation was further evidenced by
the negative results obtained when the same panel of sera was
used in an MN assay (Figure 2).
As previously shown, the detection of antibodies to avian
influenza viruses in mammalian species using HI assay can
be insensitive even in cases where experimental infection is
confirmed by virus isolation [46, 47]. Therefore, the overall
results of this comparative study could explain the extent of
antibody responses obtained from the different serological
assays (particularly HI and pp-NT). Considering the MN
assay as themore sensitive test in detecting human antibodies
to H5N1 virus in infected individuals [28], the total absence
of antibody responses detected against A/Indonesia/5/2005
in this study cannot be simply justified by the assumption
that the HAs on influenza pseudotypes are more accessible
to neutralizing antibodies compared to the wild-type virus
used in MN assay [31, 32]. Perhaps, one possible explanation
could be sought in the MN method used in the reference
laboratory as differences have been observed in other studies
when virus neutralization was detected by ELISA in viral
infected cells (using antibodies against NP), as opposed to the
observation of viral cytopathic effect.Thus, aiming to further
characterize the nature of these serological profiles obtained
using the pp-NT assay, influenza pseudotypes bearing HA
from HPAI H7 strains were also employed. The heterosub-
typic antibody response as measured by this neutralization
assay was found to be significantly higher against the Group 1
H5 pseudotype virus than against theGroup 2H7 pseudotype
virus as shown in Figure 3. In 47/68 sera, no neutralizing
antibody response was detected by the pseudotype assay
against H7, and for the sera that were found positive against
H7 titres were relatively low when tested by pp-NT.The assay
described in this study consists of two serological antigens
belonging to different HA Groups. The Group 1 subtype
H5 shares a conserved HA stalk domain with H1, which
also belongs to Group 1. The Group 2 subtype H7 shares
a conserved HA stalk domain with H3. Both H1 and H3
viruses circulate continuously within the human population
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Figure 3: Cross-reactivity antibody profiles of SRH positive human sera against a Group 1 clade 1 H5 and clade 2.1.3.2 H5 and Group 2 H7N1
H7 pseudotypes as measured using pseudotype-based neutralization assays. Antibody response colour chart showing the IC
50
neutralizing
antibody titres of 68 sera with an SRH titre > 25mm2 measured against H5 and H7 pseudotypes. Individual end-point titres (as calculated
using GraphPad) were split into 9 separate bands based on titre range and assigned an individual colour. Colour legend is reported on the
bottom of the figure.
and are able to elicit broadly specific antistalk antibodies.
Additionally, seasonal vaccination has been shown to elicit
these antibodies [48] as well as primary infection in children
[49]. As demonstrated by a precedent study where cross-
reactive anti-avian H5N1 influenza neutralizing antibodies
were found in normal “exposure-na¨ıve” Australian blood
donors [50], it is highly unlikely that the individuals sampled
in this study had ever come into contact with HPAI H5 or H7
viruses or indeed antigenically related LPAIH5 orH7 viruses.
Therefore, it is postulated that this highly sensitive neutraliza-
tion assay is measuring broadly specific antistalk antibodies
that have been elicited via exposure to H1 and H3 viruses
and/or antibodies that recognize highly conserved sequences
located underneath theRBS of individual subtypes (especially
H1N1, H3N2, and H5N1) [51]. This is supported by the HI
data, which shows that the responses measured are unlikely
to be directed against the globular head. If this is indeed
what is being measured, it suggests that H1 virus (Group 1)
exposure is responsible for a more potent cross-reactive anti-
body response than H3 virus (Group 2) exposure. This can
be explained by the fact that both H1 and H5 belong to the
same Group 1 H1a Cluster (with H2 and H6), whereas H3
belongs to the H3 Cluster (with H4 and H14) and H7
belongs to the H7 Cluster (with H10 and H15) as described
previously [10]. As the sera found sero-positive by SRH were
also analyzed to remove nonspecific antibodies (these sam-
ples were adsorbed in a 1 : 1 volume mixture of A/New Cale-
donia/20/1999 H1N1 and A/California/7/2004H3N2 viruses)
and exclude any possible cross-reactivity [36], the serum
samples found positive by pp-NT assay were tested not only
against H5 and H7 subtypes but also against H1 (H1N1
A/South Carolina/1/1918) and H3 (H3N2 A/Udorn/307/1972)
influenza pseudotypes so that additional information could
be obtained from this panel of sera (Figure 4). As expressed
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Figure 4: Cross-reactivity antibody profiles of SRH positive human sera against Group 1 H5 (A/Vietnam/1194/04, A/Indonesia/5/05) and H1
(A/SouthCarolina/1/18) and Group 2 H7 (A/chicken/Italy/13474/99) and H3 (A/Udorn/307/72) pseudotypes as measured using pseudotype-
based neutralization assays. Antibody response colour chart showing the IC
50
neutralizing antibody titres of 37 sera with an SRH titre >
25mm2 measured against H1, H3, H5, and H7 pseudotypes. Individual end-point titres (as calculated using GraphPad) were split into 9
separate bands based on titre range and assigned an individual colour.
by the percentage of positive sera (Figure 4), it was clear that
the percentage of antibody positive responses against H1 and
H3 pseudotypes were significantly higher than those seen for
H5 and H7 (with 100% positive sera when tested against H3
independently of the positive cutoff chosen), and the neu-
tralization pattern mirrored the phylogenetic relationship
(similar magnitude of responses for H1 and H5 subtypes
compared toH3 subtype).The antibody responses against H3
pseudotypes were significantly higher, however, previous
studies have also demonstrated the presence of neutralizing
activity against pandemic H1N1 and H5N1 pseudotyped
viruses [34, 42]. Based on the serology data presented in this
study, it is evident that further comparative serology studies
are warranted to elucidate the nature of the heterosubtypic
antibody responses elicited in these patients. Although results
obtained by pp-NT assay correlated significantly with those
obtained by HI and MN assays when testing avian sera [32]
and the pp-NT assay was also reported to be more sensitive
than classical MN when employed for the screening of sera
from human subjects vaccinated against H5N1 [30], the
positive threshold for pp-NT assays is still undefined and this
makes it problematic to evaluate the reproducibility of differ-
ent serological assays.
Since one of the purposes of this study was to understand
if heterosubtypic antibody responses can be detected using
influenza pseudotypes as serological tools as shown in a
previous study [14], titres between 20 and 80 were taken into
consideration. However, using the suggested positive cutoff
for pp-NT assay of 1 : 357 [30] instead of those used to define
a positive result or sero-protection by other serological assays,
the serological outcome was noticeably changed for sera
tested against HPAI H7 pseudotypes (Table 2). Although
BioMed Research International 11
the majority of sera scored positive independently of the
positive threshold used, the cutoff of 1 : 357 was unable to
identify differentiated responses for sera tested by HPAI H7
pseudotypes. Therefore, this first study demonstrated that
future refinement and further validation of this assay are
warranted for the sero-epidemiological study of human pop-
ulations. Moreover, additional aspects need to be taken into
consideration such as identification of proper assay-specific
cutoffs and internal/external controls, optimization of pseu-
dotype titres, and availability of amore comprehensive library
of influenza pseudotypes.
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